Drug
Pegcetacoplan clinical trials
Also written APL-2, Empaveli and SYFOVRE.
- studies test it
- 31
- open now
- 7
- in phase 3
- 12
- first study started
- 2015
Keep track of what changes. Save the pegcetacoplan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2018 (8)
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 8 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 13
- Phase 3
- 12
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 2
Apellis Pharmaceuticals, Inc. (24) · Swedish Orphan Biovitrum (3) · Columbia University (1) · Roswell Park Cancer Institute (1) · AbbVie (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
ABBV-6628 (1) · RO7669330 (1) · Avacincaptad pegol (1)
Studies
Open first, then newest update. How each study uses pegcetacoplan is read from its arms, and is right about nine times in ten.
Testing it · 31
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyRecruitingPhase 4Swedish Orphan BiovitrumNCT07746895Written as Pegcetacoplan
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisRecruitingPhase 2/3Apellis Pharmaceuticals, Inc.NCT07213960Written as APL2
- Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2Roswell Park Cancer InstituteNCT07214298Written as Pegcetacoplan
- Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruitingPhase 1/2AbbVieNCT07160179Written as SYFOVRE
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingPhase 2Apellis Pharmaceuticals, Inc.NCT04901936Written as Pegcetacoplan
- A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioRecruitingPhase 2Apellis Pharmaceuticals, Inc.NCT07215390Written as APL-3007, pegcetacoplan (APL-2)
- Safely Quenching Complement in Stroke SurvivorsNot yet recruitingPhase 1Columbia UniversityNCT07495722Written as Pegcetacoplan Injection [Empaveli]
- Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationWithdrawnPhase 3Apellis Pharmaceuticals, Inc.NCT07020832Written as Pegcetacoplan
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)TerminatedPhase 1Hoffmann-La RocheNCT06961370Written as Syfovre™
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT04770545Written as PEGCETACOPLAN (APL-2)
- Pegcetacoplan Long Term Safety and Efficacy Extension StudyCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT03531255Written as Pegcetacoplan
- Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNCompletedPhase 2Apellis Pharmaceuticals, Inc.NCT04572854Written as Pegcetacoplan
- An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisActive, not recruitingPhase 3Apellis Pharmaceuticals, Inc.NCT05809531Written as Pegcetacoplan
- Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT05067127Written as Pegcetacoplan
- Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT07214740Written as APL-2, Pegcetacoplan
- A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedPhase 2Swedish Orphan BiovitrumNCT05148299Written as Pegcetacoplan
- A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)CompletedPhase 3Swedish Orphan BiovitrumNCT05096403Written as Pegcetacoplan
- MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TerminatedPhase 2Apellis Pharmaceuticals, Inc.NCT04579666Written as Pegcetacoplan (APL-2)
- Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCompletedPhase 2Apellis Pharmaceuticals, Inc.NCT03453619Written as APL-2
- Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)CompletedPhase 2Apellis Pharmaceuticals, Inc.NCT03226678Written as APL-2
See all 31 studies that test pegcetacoplan →
Given in every arm · 1 — pegcetacoplan is usual care beside what is tested
As the comparator · 1 — what is tested is compared with pegcetacoplan
Codes
What other systems call pegcetacoplan · ClinicalTrials.gg INT001596
- MeSH (NLM) C000716074pegcetacoplanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TO3JYR3BOUPEGCETACOPLANConfirmed FDA, NLM, Wikidata
- RxNorm 2557372One source FDA
- Wikidata Q106863504pegcetacoplanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C121135PegcetacoplanOne source FDA
- DrugBank DB16694One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716074 | pegcetacoplan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TO3JYR3BOU | PEGCETACOPLAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2557372 | — | One source FDA |
| Wikidata | Q106863504 | pegcetacoplan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C121135 | Pegcetacoplan | One source FDA |
| DrugBank | DB16694 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.